Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease
Journal of the American Heart Association · 20.06.2023 · 12 (12)
DOI: 10.1161/jaha.122.027334 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, erschienen am 20.06.2023. Verfasst von Jung-Joon Cha und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine S…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Peripheral Arterial Disease. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
No large‐scale study has compared the clinical impact of triple antiplatelet therapy (TAPT: aspirin, clopidogrel, and cilostazol) and dual antiplatelet therapy (DAPT) on adverse limb events in patients with diabetes after endovascular therapy (EVT) for peripheral artery disease. Thus, we investigate the effect of cilostazol added to a DAPT on the clinical outcomes after EVT in patients with diabetes using a nationwide, multicenter, real‐world registry. Methods and Results A total of 990 patients with diabetes who underwent EVT were enrolled from the retrospective cohorts of a Korean multicenter EVT registry and were divided according to the antiplatelet regimen (TAPT [n=350; 35.4%] versus DAPT [n=640; 64.6%]). After propensity score matching based on clinical characteristics, a total of 350 pairs were compared for clinical outcomes. The primary end points were major adverse limb events, a composite of major amputation, minor amputation, and reintervention. For the matched study groups, the lesion length was 125.4±102.0 mm, and severe calcification was observed in 47.4%. The technical success rate (96.9% versus 94.0%; P =0.102) and the complication rate (6.9% versus 6.6%; P >0.999) were similar between the TAPT and DAPT groups. At 2‐year follow‐up, the incidence of major adverse limb events (16.6% versus 19.4%; P =0.260) did not differ between the 2 groups. However, the TAPT group showed less minor amputation than the DAPT group (2.0% versus 6.3%; P =0.004). In multivariate analysis, TAPT was an independent predictor of minor amputation (adjusted hazard ratio, 0.354 [95% CI, 0.158–0.794]; P =0.012).
Conclusions
In patients with diabetes undergoing EVT for peripheral artery disease, TAPT did not decrease the incidence of major adverse limb events but may be associated with a decreased risk of minor amputation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Cardiology, Department of Internal Medicine, Cardiovascular Center Korea University Anam Hospital, Korea University College of Medicine Seoul Republic of Korea.
- Division of Cardiology, Department of Internal Medicine, Regional Cardiocerebrovascular Center Wonkwang University Hospital Iksan Republic of Korea.
- Division of Cardiology, Department of Internal Medicine College of Medicine, Hanyang University Seoul Republic of Korea.
- Cardiovascular Center Donggunsan Hospital Gunsan Republic of Korea.
- Division of Cardiology, Department of Internal Medicine Severance Cardiovascular Hospital, Yonsei University College of Medicine Seoul Republic of Korea.
- Division of Cardiology, Department of Internal Medicine Gangnam Severance Hospital, Yonsei University College of Medicine Seoul Republic of Korea.
ORCID-Profile: Jung-Joon Cha, Jae Young Cho, Subin Lim, Ju Hyeon Kim, Hyung Joon Joo, Soon Jun Hong, Do-Sun Lim, Hyungdon Kook, Seung Hun Lee, Young-Guk Ko, Pil-Ki Min, Jae-Hwan Lee, Chang-Hwan Yoon, In-Ho Chae, Seung Whan Lee, Sang-Rok Lee, Seung Hyuk Choi, Cheol Woong Yu
Zitieren
APA
Cha, J. J., Cho, J. Y., Lim, S., Kim, J. H., Joo, H. J., Park, J. H., Hong, S. J., Lim, D. S., Kook, H., Lee, S. H., Ko, Y. G., Min, P. K., Lee, J. H., Yoon, C. H., Chae, I. H., Lee, S. W., Lee, S. R., Choi, S. H., Koh, Y. S., & Yu, C. W. (2023). Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease. Journal of the American Heart Association, 12(12). https://doi.org/10.1161/jaha.122.027334
Vancouver
Cha JJ, Cho JY, Lim S, Kim JH, Joo HJ, Park JH, et al. Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease. Journal of the American Heart Association. 2023;12(12). doi:10.1161/jaha.122.027334
BibTeX
@article{Cha2023,
author = {Cha, Jung-Joon and Cho, Jae Young and Lim, Subin and Kim, Ju Hyeon and Joo, Hyung Joon and Park, Jae Hyoung and Hong, Soon Jun and Lim, Do-Sun and Kook, Hyungdon and Lee, Seung Hun and Ko, Young-Guk and Min, Pil-Ki and Lee, Jae-Hwan and Yoon, Chang-Hwan and Chae, In-Ho and Lee, Seung Whan and Lee, Sang-Rok and Choi, Seung Hyuk and Koh, Yoon Seok and Yu, Cheol Woong},
title = {Effect of Cilostazol on Patients With Diabetes Who Underwent Endovascular Treatment for Peripheral Artery Disease},
journal = {Journal of the American Heart Association},
year = {2023},
volume = {12},
number = {12},
doi = {10.1161/jaha.122.027334}
}
EUVIMED